[go: up one dir, main page]

WO2007030531A3 - Reagents for testing and molecular imaging of liver cancer - Google Patents

Reagents for testing and molecular imaging of liver cancer Download PDF

Info

Publication number
WO2007030531A3
WO2007030531A3 PCT/US2006/034703 US2006034703W WO2007030531A3 WO 2007030531 A3 WO2007030531 A3 WO 2007030531A3 US 2006034703 W US2006034703 W US 2006034703W WO 2007030531 A3 WO2007030531 A3 WO 2007030531A3
Authority
WO
WIPO (PCT)
Prior art keywords
reagents
imaging
molecular imaging
testing
liver cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034703
Other languages
French (fr)
Other versions
WO2007030531A2 (en
Inventor
Jay M D Wohlgemuth
Kirk Fry
Rheal Antoine Towner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Molecular Image Inc
Original Assignee
Oklahoma Medical Research Foundation
Molecular Image Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, Molecular Image Inc filed Critical Oklahoma Medical Research Foundation
Publication of WO2007030531A2 publication Critical patent/WO2007030531A2/en
Publication of WO2007030531A3 publication Critical patent/WO2007030531A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention describes both the identification of disease target molecules and the development of imaging reagents and diagnostic assays specific to those molecules. Described herein are methods and reagents for the identification of molecular targets specific to a disease or disease state, methods of imaging technology which can be used, the development of specific molecular imaging reagents, clinical validation of the imaging reagents, and clinical indications for molecular imaging.
PCT/US2006/034703 2005-09-06 2006-09-06 Reagents for testing and molecular imaging of liver cancer Ceased WO2007030531A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71479005P 2005-09-06 2005-09-06
US60/714,790 2005-09-06

Publications (2)

Publication Number Publication Date
WO2007030531A2 WO2007030531A2 (en) 2007-03-15
WO2007030531A3 true WO2007030531A3 (en) 2007-11-15

Family

ID=37836417

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/034777 Ceased WO2007030571A2 (en) 2005-09-06 2006-09-06 Identification of targets and development of reagents for testing and molecular imaging of human disease
PCT/US2006/034703 Ceased WO2007030531A2 (en) 2005-09-06 2006-09-06 Reagents for testing and molecular imaging of liver cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034777 Ceased WO2007030571A2 (en) 2005-09-06 2006-09-06 Identification of targets and development of reagents for testing and molecular imaging of human disease

Country Status (1)

Country Link
WO (2) WO2007030571A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014404A2 (en) 2006-07-26 2008-01-31 The University Of Chicago Receptor-mediated delivery : compositions and methods
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
DE102008039417A1 (en) * 2008-08-13 2010-02-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Agent for the detection and treatment of prostate cells
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
US20120190049A1 (en) * 2010-12-10 2012-07-26 University Of Washington Through Its Center For Commercialization Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
US8900822B2 (en) 2011-11-21 2014-12-02 Ethicon, Inc. Fibrinogen assay
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
SMT202100180T1 (en) 2013-10-11 2021-05-07 Oxford Bio Therapeutics Ltd Conjugated antibodies against ly75 for the treatment of cancer
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
CN107328746B (en) * 2017-06-14 2020-01-31 宁波大学 Preparation and application of multifunctional fluorescent biosensors based on nucleic acid-like coordination polymers
CN111273010B (en) * 2018-12-04 2023-04-18 北京蛋白质组研究中心 Application of kit for detecting SOAT1 protein expression level in preparation of hepatocellular carcinoma screening product
US20200191785A1 (en) * 2018-12-18 2020-06-18 Euroimmun Medizinische Labordiagnostika Ag Method for Diagnosing Autoimmune Gastritis
CN109701039A (en) * 2019-01-17 2019-05-03 浙江大学 A kind of preparation method of liver cancer dual-target magnetic nanoparticle
CN109897900B (en) * 2019-03-13 2023-04-07 温州医科大学 Application of EPB42 gene in liver cancer SBRT curative effect evaluation
JP7353396B2 (en) * 2019-06-14 2023-09-29 シージーン アイエヌシー Computer processing method for collaborative development of target nucleic acid detection reagents
CN115166245A (en) * 2021-04-04 2022-10-11 兰州大学第一医院 Application of CLU and its composition in the diagnosis of cholangiocarcinoma and diagnostic kit for cholangiocarcinoma
CN113249476B (en) * 2021-05-12 2022-10-14 复旦大学 Key protein BLT2 influencing tumor cell dryness and application thereof
CN113151482A (en) * 2021-05-21 2021-07-23 深圳泰莱生物科技有限公司 Method for identifying benign and malignant lung nodules based on monochromatic multiple fluorescence quantitative PCR
CN117647645B (en) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Application of LBP, ATF6 and M-CSFR combination in preparation of product for diagnosing autoimmune liver disease and kit
CN118471472B (en) * 2024-05-22 2025-07-22 中国人民解放军海军军医大学第三附属医院 Marker, kit, system and application for screening or diagnosing early liver cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077602A1 (en) * 2000-01-31 2003-04-24 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
AU2001271621A1 (en) * 2000-06-28 2002-01-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20020122806A1 (en) * 2001-03-05 2002-09-05 Chinnaiyan Arul M. Compositions and methods for in situ and in vivo imaging of cells and tissues
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
JP4611017B2 (en) * 2002-04-30 2011-01-12 エモリー ユニバーシティー Tumor imaging compounds
AU2003303954A1 (en) * 2002-10-25 2004-10-11 Emory University Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077602A1 (en) * 2000-01-31 2003-04-24 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARIYAMA ET AL.: "Expression of MAGE-1 and -3 Genes and Gene Products in Human Hepatocellular Carcinoma", BR. J. CANCER, vol. 81, 1999, pages 1080 - 1087 *
NAKATSURA ET AL.: "Glypican-3, Overexpressed Specifically in Human Hepatocullar Carcinoma, is a Novel Tumor Marker", BIOCHEM. BIOPHYS. RES. COMM., vol. 306, 2003, pages 16 - 25, XP002261242 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238064B2 (en) 2008-03-03 2016-01-19 University Of Miami Allogeneic cancer cell-based immunotherapy

Also Published As

Publication number Publication date
WO2007030571A2 (en) 2007-03-15
WO2007030571A3 (en) 2007-08-30
WO2007030531A2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2007030531A3 (en) Reagents for testing and molecular imaging of liver cancer
WO2008036691A3 (en) Biomarkers for prostate cancer and methods using the same
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
WO2006079049A3 (en) Methods and compositions for increased dynamic range detection of nucleic acid molecules
WO2007019492A3 (en) Methods for detection of a nucleic acid by sequential amplification
ATE527383T1 (en) MULTIPLEX NUCLEIC ACID DETECTION
WO2007120265A3 (en) Coded molecules for detecting target analytes
EP2021512A4 (en) Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
WO2007008276A3 (en) Turnover probes and use thereof for nucleic acid detection
WO2008098100A3 (en) Detection of molecule proximity
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2008033575A3 (en) Methods of identifying biochemical pathways
WO2007106047A8 (en) Nucleic acid interaction analysis
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
WO2007050777A3 (en) Methods and compositions for diagnosing lung cancer with specific dna methylation patterns
WO2009019367A3 (en) Apolipoprotein ai assay method for the in vitro diagnosis of colorectal cancer
BRPI0816047A2 (en) oligonucleotide array for detection of a target nucleic acid, methods for detecting the presence or absence of a target nucleic acid and at least two target nucleic acids, kit, reaction mixture and fluorescence-identified amplicon
WO2007079284A3 (en) Lung cancer diagnostic assay
WO2007132120A3 (en) Procedure and methods for detecting alzheimer's disease
WO2008124091A3 (en) Compositions and methods of detection
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
WO2002037102A3 (en) Methods for analyzing dynamic changes in cellular informatics
WO2011051805A8 (en) Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data
WO2008108873A3 (en) Molecular biosensors for detecting macromolecules and other analytes
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06803033

Country of ref document: EP

Kind code of ref document: A2